PolyPeptide Group AG (id:13100 PPGN)
28.70 CHF
Opening hours: 09:00 - 17:20 (Central European Standard Time: 12/24/2024 5:21:13 PM)
Exchange closed, opens in 15 hours 38 minutes
About PolyPeptide Group AG
Market Capitalization 923.54M
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
| Headquarters (address) |
Neuhofstrasse 24 Baar 6340 Switzerland |
| Phone | 41 435 020 580 |
| Website | https://www.polypeptide.com |
| Employees | 1K |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | PPGN |
| Exchange | Swiss Stock Exchange |
| Currency | CHF |
| 52 week range | 14.11 - 35.80 |
| Market Capitalization | 923.54M |
| Dividend yield forward | 4.18 % |
| Dividend yield forward Switzerland (ID:153, base:162) | 12.89 % |
| P/E trailing | 108.52 |
| P/E forward | 75.68 |
| Price/Sale | 2.85 |
| Price/Book | 2.57 |
| Beta | 1.12 |
| EPS | 3.00 |
| EPS Switzerland (ID:153, base:188) | 28.46 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: PolyPeptide Group AG has raised their dividend 4.18 years in a row. This is below the 42121.883500 year average in the 'Drug Manufacturers Specialty & Generic' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: PolyPeptide Group AG has raised their dividend 4.18 years in a row. This is below the 42121.883500 year average in the 'Drug Manufacturers Specialty & Generic' industry